Bessor Pharma

Bessor Pharma is a biotechnology research company headquartered in Framingham, Massachusetts, focused on the discovery and development of novel therapeutics and technologies. The firm specializes in translational R&D, working to advance projects through proof of concept or IND-ready stages for downstream partners and investors. Its research efforts center on a unique portfolio that includes immuno-oncology, immune-inflammation, and chemical synthesis, with a notable emphasis on leveraging the renalase (RNLS) signaling pathway. The company maintains an extensive ecosystem of academic relationships, including a key collaboration with Yale University, from which it has exclusive rights to patents and research regarding RNLS-based therapeutics and diagnostics.

This research and development work is critical for addressing serious conditions where current treatment options may be limited, such as pancreatic cancer, melanoma, acute kidney injury, and the severe hyperimmune response associated with COVID-19. By developing innovative candidates like the RNLS peptide agonist BP-1002 and humanized anti-RNLS antibodies, Bessor Pharma aims to provide clinical solutions that can modulate inflammation, protect tissues, and improve patient survival rates. Its dual-track approach—combining biological therapeutic development with a proprietary chemical synthesis platform—positions the company to address significant medical needs while providing scalable, high-value opportunities within the biopharmaceutical and healthcare sectors.